Altimmune Inc (ALT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.22 (-0.62%), Market cap $0.55B, 52-week low–high $2.60 ~ $7.71.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Financial statements, price targets, institutional (13F) holdings and related news for Altimmune Inc are updated in real time on BlackAll Trade.
Altimmune Inc trades at $3.22 (-0.62%). Real-time quotes and charts are available on BlackAll Trade.
Altimmune Inc has a market cap of about $0.55B.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual rec